Sitemap

Krka is one of the leading global generic pharmaceutical companies, present in over 70 countries. The company’s extensive international business network comprises business facilities and production plants in Slovenia, and production and distribution centres in the Russian Federation, Poland, Croatia, and Germany.

Krka is the market leader in Slovenia. Krka’s presence is significant on the generic pharmaceutical markets of Eastern, Central and South-Eastern Europe, and the markets of Western Europe as well. Krka has been strengthening its appearance also on the overseas markets, especially in China, the Middle East and Far East, Africa and Americas.

Advanced pharmaceutical production and the vertically integrated business model allow Krka to provide customers with a wide range of safe, high-quality and effective prescription pharmaceuticals, non-prescription products, and animal health products. Krka focuses on high quality, safe and efficacious generic prescription pharmaceuticals marketed under Krka’s own brands. The company allocates 10% of sales revenues to research and development. More than 50 million patients take Krka’s medicines every day.

Krka focuses on generic prescription pharmaceuticals marketed under its own brands. Krka’s main therapeutic classes include pharmaceuticals for cardiovascular diseases, the gastrointestinal tract and metabolism, and central nervous system. Krka has entered new therapeutic areas, especially that of oncology medicines and antivirals, and to a certain extent, non-prescription products as well.

Krka has been expanding its marketing-and-sales network and increasing market shares by establishing its own companies and through mergers in several countries. The objective is to strengthen the Krka’s market position in Europe and in the markets of Central Asia, as well as to enter new high-potential markets. Krka has been present in China for more than 20 years. Krka established a representative office in Shanghai in 2006.

In order to increase the competitive advantage of its product portfolio, Krka allocates a large portion of its revenues to research and development. Krka has more than 170 new products in the pipeline. The major part of revenue is generated by sales of new products, i.e. products launched in various markets in the past five years.

www.krka.biz

Ningbo Menovo Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture, and sales of special active pharmaceutical ingredients (APIs), medical intermediates, and finished products.

The company’s product range comprises medicines for the digestive system and cardiovascular agents, including antihypertensives, hypolipemics, and antithrombotic agents. The company supplies its products to domestic and overseas markets.

www.menovopharm.com